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PCV75
THE APPLICATION OF TWO ANALYTIC METHODS TO
INVESTIGATE THE INFLUENCE OF POOR INR CONTROL 
ON RISKS OF HOSPITALISATION FOR PATIENTS 
RECEIVING WARFARIN
Ofori B1, Davey P1, Goudie B2,Timoney A2, Donnan P1
1University of Dundee, Dundee, Scotland, UK; 2NHS Tayside, Dundee,
Scotland, UK
OBJECTIVES: Adverse drug reactions to oral anticoagulants are
a cause of signiﬁcant morbidity. Treatment decisions will depend
on effective means of risk stratiﬁcation and a better under-
standing of changes that occur in the immediate period just
before an event. METHODS: Cox proportional hazards model-
ling and the case crossover methodology were applied to deter-
mine the hazards associated with the outcome of hospitalisation
due to bleeding or over-anticoagulation. The study population
comprised an inception cohort of 735, accumulating 583
patients years follow up. Under Cox proportional hazards mod-
elling pre-speciﬁed clinical and laboratory variables were tested,
including measures of quality of anticoagulation. Under the case-
crossover methodology changes in biochemical, haematological,
anticoagulation parameters, drug exposures, and their relation
to outcome were analysed by conditional logistic regression
analysis. Measurements from a 3-month case window immedi-
ately before the outcome event were compared to a control
window four to six months before the outcome event. In both
analyses factors univariately associated at p < 0.3 were consid-
ered in a multivariate backward-stepwise analysis. RESULTS:
Under multivariate Cox proportional hazards modelling four
variables were found to be signiﬁcantly and independently cor-
related with the outcome; % days over INR 4.4 (p < 0.001),
history of malignancy (p = 0.048), history of any bleed (p <
0.001), number of current comorbidities (p = 0.046). The case
crossover analysis suggested that patients experiencing an
outcome event were more likely to have spent time above INR
4.4 in the case period just before the event compared to the
control period. For every increase of 1% in the time spent above
INR 4.4 the odds of an event increased by 27% (95% CI
4%–54%). CONCLUSION: This study provides further evi-
dence of the importance of monitoring and reporting time spent
over INR 4.4 to minimise the risk of adverse outcomes to 
warfarin therapy.
PCV76
USING A PATTERN MIXTURE MODEL TO UNDERSTAND THE
IMPACT OF NON-RANDOM MISSING DATA IN HEALTH-
RELATED QUALITY OF LIFE AMONG PATIENTS
UNDERGOING NON-CARDIAC VASCULAR SURGERY
Lee WC1, Cappelleri JC2, Sheikh S2, Haider S2, Gold KF3,
Stephens JM1
1Abt Associates Inc, Bethesda, MD, USA; 2Pﬁzer Inc, Groton, CT, USA;
3Quanta Scientiﬁc, Silver Spring, MD, USA
OBJECTIVE: Non-randomness of missing data in longitudinal
health-related quality of life (HRQL) studies causes potential
bias of estimates using conventional generalized linear model
(GLM). The study objective was to compare a pattern mixture
model (PMM) with GLM. METHODS: HRQL data were col-
lected using the SF-12 acute at baseline and postoperative Day
30 as part of a clinical trial assessing perioperative myocardial
ischemic injury (PMII) in high-risk noncardiac vascular surgery
patients. A PMM, where the indicator variable of drop-out and
the interaction term of drop-out and the presence of PMII event
were included as covariates, was ﬁtted using physical component
scores (PCS) of SF-12 as the outcome variable. The main pre-
dictor was the presence of PMII event adjusted for a host of
control variables. This PMM was compared with a GLM where
a change in PCS on SF-12 was used as a dependent variable.
RESULTS: Of the 370 subjects in the U.S. clinical population,
229 subjects provided information on the SF-12 at baseline and
195 subjects at Day 30. Mean PCS were 30.6 (SD = 10.7) at
baseline and 32.8 (10.6) at Day 30. Drop-out was not indepen-
dent of the presence of PMII event (p = 0.0085). With the GLM
using only completed cases (N = 190), an unexpected result
emerged; the presence of PMII event was positively associated
with improvement in the PCS of SF-12. In contrast, PMM (N =
229) indicated a more realistic result of a change in direction
that, although statistically insigniﬁcant (p = 0.11), reﬂected a
detrimental effect on PCS in the presence of a PMII event. CON-
CLUSION: GLM on complete data can give a spurious result
when sicker patients are more likely to be excluded from analy-
sis. While the PMM provided a logical direction of effect, a
longer follow-up may have been necessary to detect a statisti-
cally signiﬁcant and noticeable improvement in the PCS.
PCV77
ASSESSING THE LIKELIHOOD OF FRACTURE WITH ORAL
ANTI-SPASTICITY MEDICATIONS:A CASE-CONTROL STUDY
Nichol MB1, Shi SG1, Knight TK1, Barron RL2
1University of Southern California, Los Angeles, CA, USA; 2Allergan
Corp, Irvine, CA, USA
OBJECTIVES: To estimate the odds ratio of hip or vertebral
fracture associated with oral anti-spasticity medications in a 
California Medicaid stroke/spasticity population. METHODS:
A case-control design matched each hip or vertebral fracture
patient to ﬁve patients without fracture on date of ﬁrst pre-
scription of oral spasticity medication. Oral spasticity medica-
tions were grouped according to their sedative qualities (light
headedness, somnolence or drowsiness). Logistic regression was
used to estimate adjusted odds ratios of fractures for medication
groups while controlling for patient demographics, comorbidity,
and other concurrent medications, through a propensity score
approach. RESULTS: The adjusted odds ratio of having a hip 
or vertebral fracture for patients using medication classiﬁed in
the somnolence group (Dronabinol, Lamotrigine, Riluzole or
Tizanidine) was 1.88 (p = 0.003). The odds ratio was reduced
to 1.65 after propensity score adjustment, but remained statisti-
cally signiﬁcant (p = 0.024). Light headedness and drowsiness
medication groups did not show a signiﬁcant effect on fracture.
Concurrent use of Diazepam, a member of the drowsiness 
medication group, was individually associated with the likeli-
hood of fracture (raw odds ratio = 1.48, p = 0.002; odds ratio
after propensity score adjustment = 1.39, p = 0.014). CON-
CLUSIONS: Care should be taken when prescribing sedating
oral spasticity agents in elderly stroke patients.
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PHP1
RETAIL PRICES DECREASED 30% IN FINLAND IN 1994–2003
EVEN BEFORE INTRODUCTION OF GENERIC
SUBSTITUTION:A COHORT ANALYSIS
Jormanainen V, Hahl J, Eränkö P
GlaxoSmithKline Oy, Espoo, Finland
OBJECTIVES: We followed the retail prices of the year 1994
cohort of new chemical entities (“the 1994 NCE cohort”) in
Finland until March 15, 2003, before the introduction of generic
and parallel import substitution on April 1, 2003. METHODS:
The 1994 NCE cohort did not have any sales in 1993 by deﬁn-
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ition. The follow-up was done in databases Pharmaca Fennica
(1994–2003), SLD Pharma (1993–2002), SLD Nordic
(1998–2003) and SLD Price (1997–2003). Nominal and ofﬁcial
Consumer Price Index (Statistics Finland) adjusted (real) retail
prices (RP; including 8% VAT) were used. RESULTS: From 1993
to 2003, we identiﬁed 111 marketing companies, 1196 active
substances, 2515 trade names (products) and 9606 packages. In
1994 altogether 19 marketers introduced 32 NCE’s, of which
13% (4/32) were combination products. Some 87% (28/32) of
NCE’s, and 70% (42/60) of packages survived till the end of the
follow-up period. From 1994 to 2003 mean package RP
decreased 19% in nominal and 30% in real prices. Real prices
decreased 32% in No Refund, 31% in Basic (50%), 19% in
Lower (75%) Special and 22% in Higher (100%) Special Refund
categories. CONCLUSIONS: In 1994 Finland became a member
of the European Economic Area. Since then, retail prices have
decreased markedly in Finland even before the introduction of
generic and parallel import substitution. The observed 30%
decrease in real retail prices among the survival cohort suggests
that medicines have clearly become more cost-effective.
PHP2
IMPACT OF PRESCRIBING GUIDELINES FOR 
INPATIENT ANTICOAGULATION
Blackburn JC1, Schumock GT1, Nutescu EA1,Walton SM1, Finley JM2,
Lewis RK2
1University of Illinois at Chicago, Chicago, IL, USA; 2Mercy Resource
Management Inc, Naperville, IL, USA
OBJECTIVES: Anticoagulants are widely used and represent a
class of drugs that are problem-prone and have a high potential
for adverse patient outcomes. As such, these drugs may be
amenable to the use of prescribing guidelines. However, rela-
tively little has been published on the effect of such guidelines
on clinical outcomes or costs of care. The purpose of this study
was to assess whether guidelines improve the appropriateness of
prescribing, clinical outcomes, and the costs associated with use
of anticoagulants in a sample of community hospitals in the
United States. METHODS: A retrospective analysis was per-
formed of data voluntarily collected by 15 hospitals before
(July–September 2001) and after (March–May 2002) implemen-
tation of anticoagulant prescribing guidelines. Statistical 
analyses of both patient-level and hospital-level variables were
conducted. RESULTS: Implementation of the guidelines resulted
in a signiﬁcant increase in the proportion of anticoagulants that
were prescribed appropriately (59.8% v. 86.9%, p < 0.001). The
guidelines also resulted in a shift in the type of anticoagulants
prescribed (decreased use of unfractionated heparin and
increased use of low-molecular-weight heparins). There was sug-
gestive evidence, though not statistically signiﬁcant, that the
guidelines resulted in fewer anticoagulant-associated adverse
events (total bleeding RR = 0.71) and lower costs (savings of
$56.15 per patient per day). CONCLUSIONS: While limitations
existed with the study design, sufﬁcient beneﬁts were identiﬁed
to warrant hospitals to consider use of these or similar guide-
lines on a routine basis. Clearly, additional study in this area
would be useful.
PHP3
APPLICATION OF THE DELPHI TECHNIQUE IN THE
DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR
USE IN METHADONE MAINTENANCE PROGRAMS
Herdman MJ1, Duro P2, Ibarz R1, Rajmil L3
13D Health Research, Barcelona, Spain; 2Catalan Department of
Health and Social Services; 3Catalan Agency for Health Technology
Assessment and Research, Barcelona, Spain
Methadone maintenance programs (MMP) are used to treat
opioid addiction. In Spain, there are currently no practice guide-
lines available in MMP. OBJECTIVES: The present study reports
the use of a Delphi process to develop consensus regarding spe-
ciﬁc recommendations to include in MMP guidelines for use in
Catalonia, Spain. METHODS: The ﬁrst draft of the guidelines
were reviewed to determine where recommendations might be
needed but for which evidence was lacking in the literature, and
to generate potential items for inclusion in the Delphi question-
naire. Potential items were revised by guideline authors to agree
on ﬁnal inclusion and wording. These were included in a ques-
tionnaire administered in a three round Delphi process to
develop consensus on their inclusion in the guidelines as recom-
mendations. Panelists (n = 26) were a multidisciplinary group,
and all experts in MMP. A 4-point response option was used,
and when consensus was reached on a given item it was omitted
from the following Delphi rounds. All responses were anony-
mous and questionnaire administration was by e-mail and fax.
RESULTS: The questionnaire administered in the ﬁrst round of
the Delphi process consisted of 32 items formulated as recom-
mendations and grouped into four sections: “Entry, follow-up
and ﬁnalization of MMP” (16 items) “Take home” (5 items),
methadone in pregnancy (3 items), and “other aspects” (8 items).
In the ﬁrst round, consensus was reached on 17 of the 32 items;
in the second round, on 7 items and in the third round on 4
items. In total, consensus was reached for 28 of the 32 potential
recommendations initially included. A total of 23 recommenda-
tions deriving from the Delphi process were included in the
guidelines. CONCLUSIONS: The Delphi technique was useful
in obtaining expert consensus on recommendations to be
included in these guidelines, when evidence supporting recom-
mendations was not available in the literature.
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PERSPECTIVE OF THE GENERIC MARKET IN FRANCE:
2004–2008
Le Pen C1, Moreau A2
1Aremis Consultants and Paris Dauphine University, Paris, France;
2Ratiopharm Laboratories, Paris, France
OBJECTIVES: To model the perspective of the generic drug
market in France over the 2004–2008 period, given the rapidly
increasing generic substitution rate and arrival on that market of
a large number of best-selling drugs. METHODS: We simulated
the development of the drug market under two sets of hypothe-
sis. In the ﬁrst hypothesis, we considered only the 129 molecules
which are presently available on the generic market and we froze
the substitution rate at the level reached in 2003. In the second
hypothesis we considered the 56 additional molecules, the patent
of which will expire between 2004 and 2008 and we extrapo-
lated the increase of the substitution rate observed over the last
years. We used Box-Jenkins technique to model the market evo-
lution. We made the assumption that generic ex-factory price will
be 40% below the princeps price. We ﬁnally computed the yearly
and aggregated difference between the two scenarios, from a
global market perspective and from the Health Insurance per-
spective taking into account the reimbursement rate of each 
compound. RESULTS: Over the considered period, the patent of
some of the best-selling drugs such as omeprazole, pravastatine,
simvastatine, etc. will expire. All together these drugs represent
15% of the 2003 reimbursed drug market. The substitution rate
will reach 80%, 4 years after patent expiration. This will result
in saving Health Insurance an estimated 1 billion Euro per year
as soon as 2006. The aggregated savings on the full period will
be above ﬁve billion Euros. Two-thirds of the savings will be
attributable to the new generic drugs. CONCLUSIONS: The
